Back to Journals » OncoTargets and Therapy » Volume 12

Prognostic significance of EIF4G1 in patients with pancreatic ductal adenocarcinoma

Authors Goh TS, Ha M, Lee JS, Jeong DC, Jung ES, Han ME, Kim YH, Oh SO

Received 18 January 2019

Accepted for publication 21 February 2019

Published 15 April 2019 Volume 2019:12 Pages 2853—2859

DOI https://doi.org/10.2147/OTT.S202101

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Aruna Narula

Peer reviewer comments 2

Editor who approved publication: Dr Gaetano Romano


Tae Sik Goh,1,* Mihyang Ha,2,* Jung Sub Lee,1 Dae Cheon Jeong,3 Eun Sang Jung,4 Myoung-Eun Han,2 Yun Hak Kim,5,6 Sae-Ock Oh2

1Department of Orthopaedic Surgery and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea; 2Department of Anatomy, School of Medicine, Pusan National University, Yangsan, Republic of Korea; 3Deloitte Analytics Group, Deloitte Consulting LLC, Seoul, Republic of Korea; 4Department of Bioenvironmental Energy, College of Life & Resources Science, Pusan National University, Miryang, Republic of Korea; 5Department of Anatomy and Department of Biomedical Informatics, School of Medicine, Pusan National University, Yangsan, Republic of Korea; 6Biomedical Research Institute, Pusan National University, Busan, Republic of Korea

*These authors contributed equally to this work

Background: Advances in genomics have greatly improved the survival rate in cancer patients. However, due to genetic heterogeneity, pancreatic ductal adenocarcinoma (PDAC) is still difficult to diagnose early, and its survival rate is extremely low. Therefore, we identified biomarkers that predict the prognosis of PDAC patients using independent cohort data.
Materials and methods: To develop a novel prognostic biomarker, we used the gene expression and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Kaplan–Meier survival curve using median values of genes as cutoff showed that EIF4G1 was the only statistically significant gene in the 3 cohorts. We analyzed the prognostic significance of EIF4G1 using the time-dependent area under the curve (AUC) of Uno’s C-index, the AUC value of the receiver operating characteristics (ROC) at 3 years, and multivariate Cox analysis. We also compared EIF4G1 levels between tumors and matched non-tumor tissues.
Results: EIF4G1 is the only prognostic gene in patients with PDAC, which was selected by Kaplan–Meier survival analysis. The survival curve showed that high expression of EIF4G1 was associated with poor prognosis of PDAC with a good discriminative ability in 3 independent cohorts. The risk stratifying ability of EIF4G1 was demonstrated by analyzing C-indices and AUC values. Multivariate Cox regression confirmed its prognostic significance. EIF4G1 expression was significantly higher in PDAC tissues than in the matched normal tissues.
Conclusion: EIF4G1 could be used as a novel prognostic marker for PDAC and to determine suitable treatment options.

Keywords: EIF4GI, pancreatic ductal adenocarcinoma, prognosis, GEO, TCGA



Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]